Safety, Tolerability and Efficacy of SPD503 in Treating ADHD in Children Aged 6-17
Status:
Completed
Trial end date:
2005-10-05
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effects of SPD503 compared to placebo on tasks
of sustained attention in children and adolescents aged 6-17 diagnosed with ADHD.